|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM259466964 |
| 003 |
DE-627 |
| 005 |
20231224191245.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2016 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2016.04.003
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0864.xml
|
| 035 |
|
|
|a (DE-627)NLM259466964
|
| 035 |
|
|
|a (NLM)27085202
|
| 035 |
|
|
|a (PII)S1521-6616(16)30062-6
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Lindblom, Rickard P F
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Complement Receptor 2 is increased in cerebrospinal fluid of multiple sclerosis patients and regulates C3 function
|
| 264 |
|
1 |
|c 2016
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 30.03.2017
|
| 500 |
|
|
|a Date Revised 30.03.2017
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Besides its vital role in immunity, the complement system also contributes to the shaping of the synaptic circuitry of the brain. We recently described that soluble Complement Receptor 2 (sCR2) is part of the nerve injury response in rodents. We here study CR2 in context of multiple sclerosis (MS) and explore the molecular effects of CR2 on C3 activation. Significant increases in sCR2 levels were evident in cerebrospinal fluid (CSF) from both patients with relapsing-remitting MS (n=33; 6.2ng/mL) and secondary-progressive MS (n=9; 7.0ng/mL) as compared to controls (n=18; 4.1ng/mL). Furthermore, CSF sCR2 levels correlated significantly both with CSF C3 and C1q as well as to a disease severity measure. In vitro, sCR2 inhibited the cleavage and down regulation of C3b to iC3b, suggesting that it exerts a modulatory role in complement activation downstream of C3. These results propose a novel function for CR2/sCR2 in human neuroinflammatory conditions
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Complement Receptor 2
|
| 650 |
|
4 |
|a Complement system
|
| 650 |
|
4 |
|a Multiple sclerosis
|
| 650 |
|
4 |
|a Neurodegeneration
|
| 650 |
|
4 |
|a Neuroinflammation
|
| 650 |
|
7 |
|a Complement C3
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Complement 3d
|2 NLM
|
| 650 |
|
7 |
|a Complement C1q
|2 NLM
|
| 650 |
|
7 |
|a 80295-33-6
|2 NLM
|
| 700 |
1 |
|
|a Aeinehband, Shahin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ström, Mikael
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Al Nimer, Faiez
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sandholm, Kerstin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Khademi, Mohsen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nilsson, Bo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Piehl, Fredrik
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ekdahl, Kristina N
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 166-167(2016) vom: 01. Mai, Seite 89-95
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:166-167
|g year:2016
|g day:01
|g month:05
|g pages:89-95
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2016.04.003
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 166-167
|j 2016
|b 01
|c 05
|h 89-95
|